Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod

• Published in: International immunopharmacology Vol. 121; p. 110480
• Main Authors: Fu, Dandan, Zheng, Shuting, Li, Jialin, Hu, Hua, Wang, Qingqing, Fu, Xiuyu, Li, Min, Yan, Dong, Yang, Zishan, Tian, Zhongwei, Song, Xiangfeng
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2023
• Subjects: Animals; Cytokines - metabolism; Dermatitis - pathology; Disease Models, Animal; Imiquimod - pharmacology; Immunity; Interleukin-33; Interleukin-33 - metabolism; Mice; Mice, Inbred BALB C; Psoriasis; Psoriasis - drug therapy; Skin - pathology; STAT3; Psoriasis; Interleukin-33; Immunity; STAT3
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2023.110480

•Anti-IL-33 Ab ameliorated the erythema, scaling, epidermal thickness in imiquimod-induced psoriasis-like phenotype in mice.•Anti-IL-33 Ab reduced the expression of psoriasis-related cytokines in the skin lesions.•Anti-IL-33 Ab significantly reduced Ki-67 positive cells, CD3+CD4+T cells, and CD3+CD8+T cells in the skin lesions.•Anti-IL-33 Ab treatment down-regulated the expression of phosphorylation of STAT3 and IL-33 in the skin lesions. Interleukin-33（IL-33), is constitutively expressed in the epithelial cells of the skin. It has been reported that IL-33 contributed to the severity of the disease in psoriasis-like mouse models. In the current study, we evaluated the effect of anti-IL-33 antibody (Ab) in imiquimod-induced psoriatic dermatitis in mice. Our observations showed that anti-IL-33 Ab ameliorated the erythema, scaling, epidermal thickness and spleen index. Additionally, we found anti-IL-33 Ab significantly decreased the expression of psoriasis-related cytokines. Moreover, anti-IL-33 Ab significantly reduced Ki-67 positive cells, CD3+CD4+T cells, and CD3+CD8+T cells in the skin lesions. Furthermore, anti-IL-33 Ab treatment down-regulated the expression of phosphorylation of STAT3 and IL-33 in model mouse. These results indicated that the anti-IL-33 Ab alleviated the seriousness of skin lesions, inhibited the activation of the STAT3, lymphocyte infiltration and the secretion of pro-inflammatory cytokines in imiquimod-induced psoriatic dermatitis in mice, suggesting IL-33 may be a therapeutic target for the treatment of psoriasis.